ABBV Abbvie Earnings and EPS analysis

?
Relative Growth: Rel. Growth: 77
Relative Strength: Rel. Strength: 68
Relative Valuation: Rel. Valuation: 24
Relative Profitability: Rel. Profitability: 68

EPS in 2026 (TTM): $3.55

Last Report Period Date: Jun 30, 2026

As of August this year, based on Abbvie's most recent financial report, the company's trailing twelve months EPS is $3.55. During 2025, ABBV reported a per-share earnings of $2.37, which shows a decline compared to the EPS of $2.4 recorded in 2024. Abbvie's EPS for the quarterly period ending on Jun 30, 2026 came in at $2.04.

ABBV earnings history

Historical annual and quarterly earnings per share (EPS) data for Abbvie
EPS (TTM)
$3.55
EPS Growth YoY (Quarterly)
292.3%
EPS (Quarterly)
$2.04
EPS Growth (Quarterly)
423.1%

The yearly earnings per share during 2025 was $2.37, a decline of 1.3% compared to $2.4 recorded in 2024. Over the quarter ending Jun 30, 2026, the earnings per share came in at $2.04, reflecting a 292.3% increase compared to the same quarter a year earlier. As of June 2026, the TTM EPS is $3.55. During 2024, the annual earnings per share was $2.4, representing a decrease of 12.1% compared to 2023.

ABBV EPS vs price chart

ABBV EPS growth history

Earnings per share growth rates over time
EPS Growth YoY (Quarterly)
292.3%
EPS growth YoY
-1.3%
EPS growth 3Y avg
-29.1%
EPS growth 5Y avg
-2.8%

Abbvie has recorded a growth in earnings per share of 292.3% in the past 12 months (YoY, quarterly). During the past three years, ABBV registered an average yearly EPS growth of -29.1%. Abbvie had an average annual EPS growth of -2.8% in the last five years. Over the last decade, ABBV had an average annual earnings per share growth of -2.8%.

ABBV Earnings Waterfall

Breakdown of revenue, profit and net income for Abbvie

ABBV Earnings vs Peers

What are the earnings of ABBV compared to its peers
Stock name Price to Earnings EPS grwoth 1Y EPS grwoth 3Y EPS grwoth 5Y
BMY Bristol-Myers Squibb Company 14.73 178.7% 5.3% N/A
NBIX Neurocrine Biosciences Inc 21.64 41.5% 44% 1.9%
AZN Astrazeneca plc 24.63 45.4% 46% 22%
AMGN AMGEN Inc 27.09 88.1% 5.6% 2.9%
PFE Pfizer Inc 36.93 -3.5% -37.4% -3.7%
BIIB Biogen Inc 38.17 -21.2% -25% -18.7%
LLY Lilly(Eli) & Company 42.07 95.6% 49.2% 27.5%
ABBV Abbvie Inc 74.64 -1.3% -29.1% -2.8%
GILD Gilead Sciences Inc N/A 1,700% 23.2% 132.8%

All data is based on quarterly TTM periods, unless otherwise specified.